Bio-Rad Laboratories Inc - Class A

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) develops, manufactures, and markets a broad range of products for the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which provides reagents, instruments (including its Droplet Digital PCR platform), and software for biological research, drug discovery, and biopharmaceutical production; and Clinical Diagnostics, which offers quality control products, blood typing solutions, diabetes monitoring, autoimmune testing, and infectious disease diagnostics to hospitals, reference laboratories, and transfusion medicine centers. Bio-Rad serves universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories worldwide. The company maintains a significant equity investment in Sartorius AG, a bioprocess equipment maker. With approximately 7,400 employees and roughly $2.6 billion in annual revenues, Bio-Rad operates a global network of research, development, manufacturing, and sales operations. Updated Aug 5, 2026